Skip to main content
. 2016 Oct 1;9(10):18–27.

TABLE 4.

Commonly reported adverse events occurring in at least one percent of patients in any treatment group (safety population; N=4,336)

EVENT, N (%) DAPSONE GEL, 7.5% (N=2,161) VEHICLE (N=2,175)
Nasopharyngitis 40 (1.9) 48 (2.2)
Headache 34 (1.6) 26 (1.2)
Upper respiratory tract infection 32 (1.5) 34 (1.6)
Application site dryness 26 (1.2) 22 (1.0)
Application site pruritus 23 (1.1) 14 (0.6)
Application site pain 11 (0.5) 33 (1.5)